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Our results suggest that including sirolimus in the GVHD prophy-
laxis regimen during SCT is beneficial for patients with lymphoma,
and opens the way for clinical trials assessing its optimal use in this
patient population.55
T-CELLS REDIRECTED AGAINST CD70 FOR THE IMMUNOTHERAPY OF
HEMATOLOGICAL MALIGNANCIES
Shaffer, D.1, Savoldo, B.1, Dotti, G.1, Spencer, D.1, Kenney, S.2,
Rooney, C.M.1, Gottschalk, S.1. 1Baylor College of Medicine, Texas Chil-
dren’s Hospital, The Methodist Hospital, Houston, TX; 2The University
of Wisconsin, Madison, WI.
Background:CD70 is a tumor necrosis family member that is ex-
pressed on a broad spectrum of hematological malignancies includ-
ing multiple myeloma, non-Hodgkin’s lymphomas and Hodgkin’s
disease. In contrast to other immunotherapy targets such as
CD19, CD20, or CD33, which are widely expressed in the hemato-
poietic system, CD70 expression is restricted to a subset of activated
B and T cells, reducing potential ‘collateral damage’ when targeted
by immunotherapy. Preclinical studies in animal models using
monoclonal antibodies have validated CD70 as an immunothera-
peutic target and the aim of this study was to generate CD70-spe-
cific T cells for adoptive immunotherapy approaches. Methods &
Results: To create CD70-specific T cells we constructed
a CD70-specific chimeric antigen receptor (CD70-CAR) consisting
of domains derived from the CD70 receptor (CD27) and the T-cell
receptor CD3-z chain. CD70-specific T cells were generated by
transducing CD3/CD28-activated T cells with a SFG retroviral
vector encoding the CD70-CAR construct and cell surface expres-
sion was confirmed by FACS analysis. CD70-specific T cells from
healthy donors proliferated and produced IFN-g as well as IL-2
in contrast to mock transduced T cells after coculture with
CD70-positive myeloma cells (U266 and ARH-77) and lympho-
blastoid cell lines. In cytotoxicity assays, CD70-specific T cells
killed CD70-positive myeloma cell lines and lymphoblastoid cell
lines where as activated lymphocytes that express CD70 at low levels
and CD70-negatvie targets were not killed. Conclusion: We have
successfully constructed a CD70-CAR and demonstrate that
CD70-specific T cells selectively recognize and kill malignant cells
that express CD70 high levels. Murine xenograft studies are in
progress to confirm these findings in vivo. Adoptive immunother-
apy with CD70-specific T cells may represent a promising immuno-
therapeutic approach for CD70-positive hematological
malignancies.56
VACCINATION WITH DC/MM FUSIONS IN CONJUNCTION WITH STEM
CELL TRANSPLANTATION
Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Bissonnette, A.2, MacNamara, C.2,
Uhl, L.1, Lenahan, C.1, Miller, K.1, Joyce, R.1, Levine, J.D.1, Lowe, K.1,
Dombagoda, D.1, Richardson, P.2, Anderson, K.2, Munshi, N.2,
Kufe, D.2, Avigan, D.1. 1Beth Israel Deaconess Medical Center; 2Dana
Farber Cancer Institute.
Autologous transplantation results in the transient reversal of tu-
mor mediated tolerance due to the reduction in disease bulk, the de-
pletion of regulatory T cells, and the increase in tumor reactive
lymphocytes during the period of lymphopoietic reconstitution.
As a result, cancer vaccines are being explored as a means of target-
ing residual myeloma cells following transplant. We developed
a cancer vaccine in which patient derived tumor cells are fused
with autologous dendritic cells (DCs). We are conducting a study
in which patients with multiple myeloma (MM) undergo stem cell
transplant followed by vaccination with DC/MM fusions. DCs
were generated from adherent mononuclear cells cultured with
GM-CSF and IL-4 for 5–7 days and matured with TNFa. MM cells
were isolated from bone marrow aspirates and were identified by
their expression of CD38, CD138, and/or MUC1. DC and MMcells were fused with polyethylene glycol. Fusion cells were quanti-
fied by determining the percentage of cells that coexpress unique
DC and MM antigens. To date, 19 patients have been enrolled
and 18 have completed vaccine generation. Mean yield of the DC
and MM cells was 1.84  108 and 8.3  107 cells, respectively.
Mean fusion efficiency was 40% and the mean dose of fusion cells
generated was 4.3  106. As a measure of their immunologic po-
tency, fusion cells prominently stimulated allogeneic T cell prolif-
eration in vitro. Mean stimulation indexes were 12, 57, and 31 for
T cells stimulated by MM cells, DCs, and fusion cells, respectively.
6 patients have completed follow up and 3 are undergoing vaccina-
tion. 3 patients demonstrated resolution of post-transplant parapro-
tein following vaccination. 1 patient with disease progression early
post-transplant demonstrated initial response then disease stabiliza-
tion with vaccination. We are examining the effect of vaccination on
measures of anti-tumor immunity and levels of activated as com-
pared to regulatory T cells. In preliminary studies, an increase in
the ratio of activated (CD4/CD25low) to regulatory (CD4/
CD25high) T cells was observed. To date, all evaluable patients dem-
onstrated evidence of vaccine stimulated anti-tumor immunity as
manifested by a rise in IFNg expression by CD4 and/or CD81 T
cells in response to ex vivo exposure to autologous tumor lysate.
In this ongoing study, fusion cell vaccination followjng stem cell
transplant has been well tolerated, induced anti-tumor immunity
and clinical responses in patients with MM.PEDIATRIC DISORDERS57
PREDICTIVE VALUE OF MRD PRIOR TO ALLOGENEIC SCT IN RELAPSED
CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA – ANALYSIS OF THE
ALL-REZ BFM GROUP
Bader, P.1, Eckert, C.2, Kreyenberg, H.1, Reising, M.1, Borckhardt, A.3,
Peters, C.4, Henze, G.2, Klingebiel, T.1, Stackelberg, A.V.2. 1 JWGoethe
University Children’s Hospital, Frankfurt, Germany; 2Charite Berlin,
Berlin, Germany; 3University Medical Center, Duesseldorf, Germany;
4St. Anna Kinderspital, Vienna, Austria.
Minimal residual disease (MRD) quantified prior to allogeneic
stem cell transplantation (SCT) has been shown to predict outcome
in children with relapsed acute lymphoblastic leukemia (ALL) in
retrospective meta analysis. Within the ALL-REZ BFM Group
we have started a prospective trial evaluating the impact of pre-
transplant MRD load in a well defined group of children who re-
ceived their transplant in second or subsequent remission.
Patients: Between March 1999 and July 2005, 91 children with
relapsed ALL treated according to the protocols ALL-REZ BFM
96 or 2002 and receiving allogeneic SCT in 2nd (n 5 77) or 3rd
CR (n 5 14) have been enrolled. MRD quantification was per-
formed within 40 days prior to SCT by real time PCR using T-
cell receptor and immunoglobulin gene rearrangements as clone-
specific targets with at least 1 marker with a sensitivity of 10–4.
Results: Probability of event free survival (pEFS) in 45 patients
with MRD $10–4 was 0.27 (60.07) compared with 0.60 (60.08)
in 46 patients with MRD\10–4 (p 5 0.036). Clinical and thera-
peutical parameters were equally distributed between both sub-
groups. The difference in pEFS was more prominent in
intermediate risk patients (S2, n 5 35, 0.20 (60.12) versus 0.68
(60.12), (p 5 0.02)) than in high risk patients (S3/S4/CR3, n 5
56, 0.30 (60.09) versus 0.50 (60.11), (p 5 0.006)). Multivariate
Cox regression analysis revealed MRD as the only independent pa-
rameter predictive for EFS (p5 0.006).Conclusion: MRD prior to
allogeneic SCT proves to be the most important risk factor for out-
come post transplantation. Early prediction of MRD response until
SCT is necessary to allow timely experimental interventions in pa-
tients with persistent high level MRD. New strategies with modified
SCT procedures including conditioning regimen, graft manipula-
tion, and GVHD prophylaxis and/or post transplant intervention
strategies should be evaluated to improve the antileukemic efficacy
post SCT in patients with a high probability of subsequent relapse.
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Gluckman, E.2, Kurtzberg, J.4, O’Meara, A.7. 1UMCUtrecht, Utrecht,
Netherlands; 2EUROCORD/St. Louis, Paris, France; 3Royal Manches-
ter Children’s Hospital, Manchester, United Kingdom; 4Duke Univer-
sity, Durham, NC; 5University of North Carolina, Chapel Hill, NC;
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Hurlers syndrome (HS), the most severe form of mucopolysac-
charidosis type-I causes progressive deterioration of the central ner-
vous system and death in childhood. Allogeneic-stem cell
transplantation (SCT) before the age of two years halts disease pro-
gression and prolongs life. Graft-failure and mixed-chimerism (40–
50%) limit the success of SCT for HS. Unrelated-cord blood trans-
plants (UCBT) are suggested to be a good alternative option for
bone marrow, however, little is known about risk factors for out-
comes after UCBT for this disease. We have analyzed 93 HS chil-
dren that received an UCBT from 1995 to 2007 and were reported
to EUROCORD or transplanted at Duke University. Median age at
UCBT was 1.3 (0.2–4) yrs, and median follow up was 24 (3–140)
mths. The donor was HLA-identical (HLA-A and B by low resolu-
tion and HLA-DRB1 by high-resolution) in 15 cases (16%) and in-
compatible in 78 cases (84%: most with 1 (62%) and 2(34%) HLA
disparities). The median nucleated cell dose/kg and CD341/kg at
infusion were respectively 7.2 (2–22)x107 and 2.3 (0.5–17)x105.
With the exception of 5 patients, all received a Busulfan/Cyclophos-
phamide (1Fludarabine: 6) regimen. All patients received ATG or
Campath (4).
Results:Median days to neutrophil and platelet recovery were 22
(10–46) and 35 (13–82) days, respectively. Mixed-chimerism was
found in only 4%. All patients had normal enzymlevels. All patients
had normal enzyme levels after engraftment. In multivariate analy-
ses for neutrophil recovery, a CD341-dose of .2.3  105/kg (HR
5 2.0; p5 0.015) was associated with increased probability of recov-
ery. Acute-GvHD (grade II-IV) was observed in 27%, while
chronic-GvHD was seen in 10% at 2 years. Two years overall sur-
vival (OS) and disease/event free survival were 78% and 70%, re-
spectively. For 2 years OS, time from diagnosis to UCBT more
than 6 months was associated with increased risk of death (6% for
those children transplanted earlier and 30% for those transplanted
later: p5 0.04). Transplantation improved somatic features of HS.
In conclusion, outcomes following UCBT for Hurlers syn-
drome are encouraging. UCB appears to be a good alternative allo-
geneic stem cell source to transplant children with HS, and is
associated with a very low incidence of mixed-chimerism. Earlier
transplantation and higher cell dose are associated with better out-
comes after UCBT for HS patients.59
TNF-a AND TNF RECEPTOR SUPERFAMILY MEMBER 1B POLYMOR-
PHISMS PREDICT RISK OF ACUTE GVHD FOLLOWING MATCHED UNRE-
LATED DONOR BMT IN CHILDREN
Goyal, R.K.1, Fairfull, L.2, Livote, E.3, Yanik, G.4, Ferrell, R.E.2,
Schultz, K.5, Zorich, G.P.1, Atlas, M.3. 1Children’s Hospital of Pitts-
burgh, Pittsburgh, PA; 2University of Pittsburgh, Pittsburgh, PA;
3Schneider Children’s Hospital/Albert Einstein College of Medicine,
New York, NY; 4University of Michigan Medical Center, Ann Arbor,
MI; 5University of British Columbia, Vancouver, BC, Canada; 6Pediat-
ric Blood and Marrow Transplant Consortium.
Tumor necrosis factor-alpha (TNF-a) plays a significant role in
the conditioning related toxicities and development of acute
GvHD (aGvHD). In this study, we sought to examine if specific
polymorphisms in TNF pathway genes were associated with risk
of aGvHD. Single nucleotide polymorphisms (SNPs) in TNF-a;
and TNF receptor superfamily member 1A (TNFRSF1A) and 1B
(TNFRSF1B) were investigated; we selected SNPs with minor al-
lele frequency of $10% (13 in all) and TNF-a d microsatellite. Ina multi-institutional trial, 180 eligible patients (mean age 10 y, me-
dian 11, range 6 m-20 y) were prospectively evaluated for clinical
outcomes after 6/6 matched unrelated donor marrow transplants.
All patients received myeloablative conditioning and two drug
GvHD prophylaxis with cyclosporine or tacrolimus, majority with
methotrexate. Overall, 62% patients developed aGvHD (13%
grade I, 21% grade II, 13% grade III and 5% grade IV). Genotyping
was performed on pretransplant host peripheral blood genomic
DNA samples. TNF-a: Grade II-IV aGvHD was associated with
the variant A allele of -238 (G/A) (RR 1.7, CI 1.3, 2.5; p\ 0.01)
and variant T allele of -857 (C/T) (RR 2, CI 1.1, 3.9; p5 0.01). Se-
vere (grade III-IV) aGvHD was associated with variant A allele of -
863(C/A) (RR 2, CI 1.1, 3.3; p5 0.04) and variant C allele of -1031
(T/C) (RR 1.7, CI 1, 3.3; p5 0.05). 17/52 patients with TNF-a d3/
d3 genotype (33%) versus 68/126 with other TNF-a d genotypes
(54%) were associated with grade II-IV aGvHD (RR 0.6, CI 0.4,
0.9; p\ 0.01). TNF-a d4/d4 genotype was associated with greater
risk of aGvHD (RR 1.4, CI 1.1–1.6, p5 0.03). TNFRSF1A: No sig-
nificant correlation was observed between any of the five selected
SNPs and risk of aGvHD in this cohort. TNFRSF1B: Exon 6 cod-
ing SNP 676 (T/G) results in a juxtamembrane inversion from me-
thionine to arginine (TNFRSF1BMET/ARG); this variant is
associated with increased risk of inflammatory disorders such as lu-
pus and ulcerative colitis. 11/14 (79%) with SNP 676 (T/G) GG ge-
notype versus only 21/50 (42%) with GT and 52/109 (48%) with
TT genotypes developed grade II-IV aGvHD; the relative risk
(RR) with variant GG genotype was 1.7 (CI, 1.2, 2.4; p 5 0.02).
In conclusion, we have observed clinically important relationships
between genetic polymorphisms in TNF-a and a coding SNP in
TNFRSF1B versus occurrence and severity of acute GvHD in
this cohort. Improved understanding of this relationship may allow
for a risk-adjusted approach to GVHD prevention.60
OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
FOR NON-HODGKIN LYMPHOMA (NHL) IN CHILDREN AND ADOLES-
CENTS
Hale, G.A.1, He, V.2, Termuhlen, A.M.3, Davies, S.M.4,
Camitta, B.M.2, Cairo, M.S.5, Eapen, M.2, Gross, T.G.3. 1St. Jude
Children’s Hospital Research Hospital; 2Medical College of Wisconsin;
3Nationwide Children’s Hospital; 4Cincinnati Children’s Hospital Med-
ical Center; 5New York Presbyterian Hospital.
Introduction: Though cure rates for NHL in children and ado-
lescents are$80%, salvage rates are poor. The role of HSCT is dif-
ficult to determine from the literature as published reports include
few patients (N5 10–20) and usually from single centers.Methods:
Included are 247 patients with NHL aged#18 yrs who received au-
tologous (N5 134) or allogeneic (N5 123; 76 matched sibling and
47 unrelated donor) HSCT in 1975–2005 and reported to the Cen-
ter for International Blood and Marrow Transplant Research. Re-
sults: The median ages of patients undergoing autologous and
allogeneic transplantation were 14 years and 12 years, respectively.
23% of autologous transplants were performed in CR1, 39% in
CR2 and 38% in $CR3, relapse or induction failure. 23% of allo-
geneic transplants were performed in CR1, 33% in CR2 and 44% in
$CR3, relapse or induction failure. Patients with large cell lym-
phoma (DLBCL and ALCL) were more likely to receive autologous
HSCT, whereas those with small cell lymphoma (Burkitt and lym-
phoblastic) were more likely to receive allogeneic HSCT. Charac-
teristics of recipients of matched sibling and unrelated donor
HSCT were similar except that very few unrelated donor HSCT re-
cipients were in first clinical remission (CR1) at transplantation.
Shown below are the probabilities of transplant-related mortality
(TRM, relapse and progression-free survival (PFS) rates. The prob-
ability estimates after allogeneic HSCT for DLBCL and ALCL
should be interpreted with caution as patient numbers are small.
Further, small numbers of patients in each of the disease categories
prevented comparison of outcomes after autologous and allogeneic
HSCT. Conclusion: Autologous or allogeneic HSCT can salvage
30–50% of children and adolescents with high-risk or recurrent
NHL. TRM is are lower after autologous HSCT and relapse is
